Full Press Release Details
Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease.
In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials are evaluating safety, tolerability, and early signals of activity across multiple B cell-mediated conditions, including lupus nephritis, rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies (IIM), and systemic sclerosis.
Through these trials, we aim to better understand shared disease mechanisms and guide future development priorities. This strategy reflects our broader goal of validating AlloNK® as an outpatient-ready immunotherapy platform with the potential for broad application across autoimmune indications.
Read the full Q&A here .